Christopher McCabe

6.9k total citations · 1 hit paper
115 papers, 3.9k citations indexed

About

Christopher McCabe is a scholar working on Economics and Econometrics, General Health Professions and Cancer Research. According to data from OpenAlex, Christopher McCabe has authored 115 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Economics and Econometrics, 32 papers in General Health Professions and 11 papers in Cancer Research. Recurrent topics in Christopher McCabe's work include Health Systems, Economic Evaluations, Quality of Life (67 papers), Pharmaceutical Economics and Policy (21 papers) and Healthcare cost, quality, practices (20 papers). Christopher McCabe is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (67 papers), Pharmaceutical Economics and Policy (21 papers) and Healthcare cost, quality, practices (20 papers). Christopher McCabe collaborates with scholars based in United Kingdom, Canada and New Zealand. Christopher McCabe's co-authors include Karl Claxton, Anthony J. Culyer, Aki Tsuchiya, Devidas Menon, Tania Stafinski, Richard Edlin, Peter Hall, John Brazier, Katherine Stevens and Mike Paulden and has published in prestigious journals such as Nature, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Christopher McCabe

115 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The NICE Cost-Effectiveness Threshold

2008 605 citations Christopher McCabe, Karl Claxton et al. PharmacoEconomics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher McCabe United Kingdom	33	1.9k	817	494	487	313	115	3.9k
Allan Wailoo United Kingdom	40	1.7k 0.9×	776 0.9×	252 0.5×	440 0.9×	262 0.8×	123	4.6k
Feng Xie Canada	34	1.4k 0.7×	725 0.9×	470 1.0×	692 1.4×	352 1.1×	241	4.4k
Brett Hauber United States	35	3.1k 1.6×	1.3k 1.5×	569 1.2×	297 0.6×	648 2.1×	192	6.2k
Joseph Lipscomb United States	39	1.5k 0.8×	767 0.9×	1.9k 3.8×	751 1.5×	650 2.1×	147	5.8k
Eddy Adang Netherlands	38	785 0.4×	1.1k 1.4×	788 1.6×	1.2k 2.4×	817 2.6×	171	6.4k
Juan Oliva Spain	36	1.3k 0.7×	1.0k 1.3×	175 0.4×	395 0.8×	312 1.0×	167	4.3k
Peter Lindgren Sweden	39	1.6k 0.9×	380 0.5×	200 0.4×	709 1.5×	302 1.0×	181	4.4k
Andrea Manca United Kingdom	35	1.8k 1.0×	846 1.0×	244 0.5×	736 1.5×	340 1.1×	108	4.6k
Suzy Paisley United Kingdom	28	884 0.5×	564 0.7×	317 0.6×	320 0.7×	134 0.4×	75	3.2k
Hendrik Koffijberg Netherlands	30	691 0.4×	334 0.4×	286 0.6×	355 0.7×	251 0.8×	167	3.6k

Countries citing papers authored by Christopher McCabe

Since Specialization

Citations

This map shows the geographic impact of Christopher McCabe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher McCabe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher McCabe more than expected).

Fields of papers citing papers by Christopher McCabe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher McCabe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher McCabe. The network helps show where Christopher McCabe may publish in the future.

Co-authorship network of co-authors of Christopher McCabe

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher McCabe. A scholar is included among the top collaborators of Christopher McCabe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher McCabe. Christopher McCabe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Paulden, Mike, Chris Sampson, James F. O’Mahony, et al.. (2023). Logical Inconsistencies in the Health Years in Total and Equal Value of Life-Years Gained. Value in Health. 27(3). 356–366. 3 indexed citations

Pollard, Samantha, Deirdre Weymann, Sarah Wordsworth, et al.. (2022). Defining a Core Data Set for the Economic Evaluation of Precision Oncology. Value in Health. 25(8). 1371–1380. 11 indexed citations

Paulden, Mike & Christopher McCabe. (2021). Modifying NICE’s Approach to Equity Weighting. PharmacoEconomics. 39(2). 147–160. 16 indexed citations

Ali, Samina, Terry P. Klassen, Lawrence Richer, et al.. (2020). Study protocol for two complementary trials of non-steroidal or opioid analgesia use for children aged 6 to 17 years with musculoskeletal injuries (the No OUCH study). BMJ Open. 10(6). e035177–e035177. 7 indexed citations

Wordsworth, Sarah, Brett Doble, Katherine Payne, et al.. (2018). Using “Big Data” in the Cost-Effectiveness Analysis of Next-Generation Sequencing Technologies: Challenges and Potential Solutions. Value in Health. 21(9). 1048–1053. 17 indexed citations

Hulme, Claire, Peter Hall, Bethany Shinkins, et al.. (2018). PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Cost effectiveness analysis results. Annals of Oncology. 29. viii703–viii703. 6 indexed citations

Smith, Alison, Peter Hall, Claire Hulme, et al.. (2017). Cost-effectiveness analysis of PET-CT-guided management for locally advanced head and neck cancer. European Journal of Cancer. 85. 6–14. 27 indexed citations

Stein, Robert C., Janet Dunn, John M.S. Bartlett, et al.. (2016). OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. Health Technology Assessment. 20(10). 1–202. 55 indexed citations

McCabe, Christopher, Mike Paulden, James F. O’Mahony, Richard Edlin, & Anthony J. Culyer. (2015). Life At A Premium: Considering An End-Of-Life Premium In Value-Based Reimbursement. Value in Health. 18(3). A6–A7. 4 indexed citations

10.

Paulden, Mike, James F. O’Mahony, Anthony J. Culyer, & Christopher McCabe. (2014). Some Inconsistencies in NICE’s Consideration of Social Values. PharmacoEconomics. 32(11). 1043–1053. 43 indexed citations

11.

Bubela, Tania & Christopher McCabe. (2013). Value-Engineered Translation for Regenerative Medicine: Meeting the Needs of Health Systems. Stem Cells and Development. 22(1_suppl). 89–93. 13 indexed citations

12.

Stafinski, Tania, et al.. (2011). Health Technology Funding Decision-Making Processes Around the World. PharmacoEconomics. 29(6). 475–495. 54 indexed citations

13.

Hall, Peter, Claire Hulme, Christopher McCabe, et al.. (2011). Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer. PharmacoEconomics. 29(5). 415–432. 44 indexed citations

14.

McCabe, Christopher, Tania Stafinski, Richard Edlin, & Devidas Menon. (2010). Access with Evidence Development Schemes. PharmacoEconomics. 28(2). 143–152. 65 indexed citations

15.

McCabe, Christopher, Richard Edlin, & Jeff Round. (2010). Economic Considerations in the Provision of Treatments for Rare Diseases. Advances in experimental medicine and biology. 686. 211–222. 27 indexed citations

16.

Menon, Devidas, Christopher McCabe, Tania Stafinski, & Richard Edlin. (2010). Principles of Design of Access with Evidence Development Approaches. PharmacoEconomics. 28(2). 109–111. 28 indexed citations

17.

McCabe, Christopher, et al.. (2008). The NICE Cost-Effectiveness Threshold: What it is and What that Means. MPRA Paper. 32 indexed citations

18.

McCabe, Christopher, Lothar Bergmann, Nicholas Bosanquet, et al.. (2008). Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective. Annals of Oncology. 20(3). 403–412. 52 indexed citations

19.

McCabe, Christopher, Katherine Stevens, Jennifer Roberts, & John Brazier. (2004). Health state values for the HUI 2 descriptive system: results from a UK survey. Health Economics. 14(3). 231–244. 60 indexed citations

20.

Brazier, John, Colin Green, Christopher McCabe, & Katherine Stevens. (2003). Use of visual analog scales in economic evaluation. Expert Review of Pharmacoeconomics & Outcomes Research. 3(3). 293–302. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact